Last reviewed · How we verify
Flovent Fluticasone HFA
Fluticasone propionate is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator production.
Fluticasone propionate is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator production. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Flovent Fluticasone HFA |
|---|---|
| Also known as | Flovent |
| Sponsor | SkyePharma AG |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone propionate exerts its anti-inflammatory effects by binding to intracellular glucocorticoid receptors in airway epithelial and immune cells, leading to suppression of pro-inflammatory cytokine and chemokine production. This reduces airway edema, mucus secretion, and recruitment of inflammatory cells, thereby improving airflow and reducing asthma symptoms. The HFA (hydrofluoroalkane) formulation delivers the drug directly to the lungs via metered-dose inhaler.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (PHASE4)
- Advair HFA in Healthy and HAPE Predisposed Subjects (PHASE1, PHASE2)
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
- Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS). (PHASE2)
- Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418) (PHASE4)
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes (NA)
- Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flovent Fluticasone HFA CI brief — competitive landscape report
- Flovent Fluticasone HFA updates RSS · CI watch RSS
- SkyePharma AG portfolio CI